Back to Search Start Over

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

Authors :
van Vollenhoven R
Voskuyl A
Bertsias G
Aranow C
Aringer M
Arnaud L
Askanase A
Balážová P
Bonfa E
Bootsma H
Boumpas D
Bruce I
Cervera R
Clarke A
Coney C
Costedoat-Chalumeau N
Czirják L
Derksen R
Doria A
Dörner T
Fischer-Betz R
Fritsch-Stork R
Gordon C
Graninger W
Györi N
Houssiau F
Isenberg D
Jacobsen S
Jayne D
Kuhn A
Le Guern V
Lerstrøm K
Levy R
Machado-Ribeiro F
Mariette X
Missaykeh J
Morand E
Mosca M
Inanc M
Navarra S
Neumann I
Olesinska M
Petri M
Rahman A
Rekvig OP
Rovensky J
Shoenfeld Y
Smolen J
Tincani A
Urowitz M
van Leeuw B
Vasconcelos C
Voss A
Werth VP
Zakharova H
Zoma A
Schneider M
Ward M
Source :
Annals of the rheumatic diseases [Ann Rheum Dis] 2017 Mar; Vol. 76 (3), pp. 554-561. Date of Electronic Publication: 2016 Nov 24.
Publication Year :
2017

Abstract

Objectives: Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.<br />Methods: An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.<br />Results: The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.<br />Conclusions: The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.<br /> (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)

Details

Language :
English
ISSN :
1468-2060
Volume :
76
Issue :
3
Database :
MEDLINE
Journal :
Annals of the rheumatic diseases
Publication Type :
Academic Journal
Accession number :
27884822
Full Text :
https://doi.org/10.1136/annrheumdis-2016-209519